UniQure Expects To Resolve FDA Clinical Hold Within Three Months
Executive Summary
The gene therapy EtranaDez for hemophilia B placed on clinical hold after a patient was diagnosed with liver cancer, but UniQure points to that patient’s extensive history of liver disease.
You may also be interested in...
Signs Of Long-Term Efficacy Boost UniQure’s Hem B Gene Therapy
Unveiling its latest data, UniQure is tipped to avoid the knockback which affected BioMarin’s hemophilia A gene therapy, with a filing expected in the second half of 2021.
After Hemophilia Deal, UniQure Sees Zolgensma As Model For Huntington’s Gene Therapy
While M&A-hungry investors were disappointed in no sale, uniQure now aims to pivot toward Huntington’s – and sees Zolgensma as an example to follow.
uniQure Hemophilia B Deal With CSL Leaves M&A Fans Miffed
Observers have been expecting uniQure to be sold off as a whole but the Netherlands-based firm has chosen to sell just one asset - EtranaDez - and focus on advancing its Huntington’s disease gene therapy.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports